🇺🇸 IPILIMUMAB in United States

10,319 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Malignant Neoplasm Progression — 1,720 reports (16.67%)
  2. Diarrhoea — 1,548 reports (15%)
  3. Colitis — 1,355 reports (13.13%)
  4. Pyrexia — 1,014 reports (9.83%)
  5. Death — 963 reports (9.33%)
  6. Fatigue — 834 reports (8.08%)
  7. Off Label Use — 794 reports (7.69%)
  8. Nausea — 752 reports (7.29%)
  9. Pneumonitis — 691 reports (6.7%)
  10. Vomiting — 648 reports (6.28%)

Source database →

IPILIMUMAB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is IPILIMUMAB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for IPILIMUMAB in United States?

Marketing authorisation holder not available in our data.